BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Blueprint Medicines 



Cambridge  Massachusetts  02140  U.S.A.
Phone: 617-585-2033 Fax: n/a


SEARCH JOBS




Industry
Biotechnology






 Company News
As Market Froths, Blueprint Medicines (BPMC) Debuts $147 Million IPO for Massachusetts' Biggest Recent IPO 4/30/2015 6:14:42 AM
Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression In Models Of Hepatocellular Carcinoma 4/24/2015 10:47:38 AM
Blueprint Medicines Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity Of BLU-285 In Treatment-Resistant GIST And On Novel Cancer Drug Targets 4/20/2015 6:07:42 AM
Fidelity CEO Uses Personal Fortune to Bet on Cancer Related IPOs Like Coherus, Adaptimmune and Blueprint Medicines 4/10/2015 6:06:18 AM
Blueprint Medicines To Present New Preclinical Data On BLU-285 In Treatment-Resistant GIST And On Novel Cancer Drug Targets At Upcoming American Association for Cancer Research Annual Meeting 4/8/2015 7:43:21 AM
Blueprint Medicines Files Registration Statement for Proposed Initial Public Offering 3/24/2015 6:58:28 AM
With Alexion (ALXN) Deal in Hand, Blueprint Medicines Preps for $100 Million IPO 3/24/2015 6:06:57 AM
Blueprint Medicines Appoints Charles A. Rowland, Jr. To Its Board Of Directors 3/23/2015 7:23:18 AM
Blueprint Medicines Publishes Preclinical Proof-Of-Concept Data On Promising New Therapy For Patients With Genomically Defined Hepatocellular Carcinoma 3/16/2015 7:35:42 AM
Blueprint Medicines Strikes $265 Million Deal With Alexion Pharmaceuticals Inc. (ALXN) 3/3/2015 7:26:15 AM
1234